A Phase 2A Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis

Trial Profile

A Phase 2A Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Pharmacokinetics
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2017 Data from this trial will be presented at the 2017 Annual Meeting of the American Academy of Dermatology (AAD), according to a Sanofi and Regeneron joint media release.
    • 19 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 03 Jun 2016 Status of the trial is completed in Czech Republic (end date: 2016-03-14) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top